Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
60
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 78 publications
(63 citation statements)
references
References 28 publications
3
60
0
Order By: Relevance
“…Only one out of 12 patients (8·3%) without these risk factors experienced HZ following the addition of patients’ age (>56 years) to the risk factors in the present study. The incidence is equivalent to previous studies that used long‐term antiviral prophylaxis or vaccination (Kawamura et al , ; Winston et al , ). In contrast, one patient experienced HZ before engraftment in the clean room (7 days after auto‐HSCT), increasing the risk of outbreak.…”
Section: Univariate Analysis For Cumulative Incidence Of Herpes Zostersupporting
confidence: 62%
“…Only one out of 12 patients (8·3%) without these risk factors experienced HZ following the addition of patients’ age (>56 years) to the risk factors in the present study. The incidence is equivalent to previous studies that used long‐term antiviral prophylaxis or vaccination (Kawamura et al , ; Winston et al , ). In contrast, one patient experienced HZ before engraftment in the clean room (7 days after auto‐HSCT), increasing the risk of outbreak.…”
Section: Univariate Analysis For Cumulative Incidence Of Herpes Zostersupporting
confidence: 62%
“…[24][25][26] In the autologous HSCT recipients, the candidate ZV IN vaccine was 64% efficacious in preventing confirmed cases of HZ. 27 RZV is a vaccine consisting of the truncated form of VZV glycoprotein E (gE) and the AS01 B adjuvant system and is licensed as a 2-dose schedule in adults ≥50 years of age. 19 In phase 3 clinical studies in immunocompromised adults, this 2-dose schedule was completed in 1-2 months.…”
Section: Introductionmentioning
confidence: 99%
“…10,11 Recently, a HZ vaccine inactivated by gamma irradiation was tested in patients who underwent autologous stem cell transplantation. 9 A total of 1230 patients were randomly assigned to the vaccine consistency lot, high-antigen lot or placebo groups. After a mean of 2.4 years, the estimated vaccine efficacy in reducing HZ infection was 63.8%.…”
Section: Efficacy Of the Herpes Zoster Vaccines In Sle Patientsmentioning
confidence: 99%
“…7 Subunit and inactivated HZ vaccines have recently been studied and demonstrated efficacy in both immunocompetent and immunocompromised individuals. [8][9][10][11] As they are not live-virus vaccines, they offer the opportunity for immunocompromised subjects to be immunized for protection against HZ reactivation. In this article, the current status of HZ vaccination in patients with SLE is discussed.…”
Section: Introductionmentioning
confidence: 99%